Viking Therapeutics Shares Plunge 15% Following Upsized Offering Pricing

Key Facts

Amid intense selling pressure driven by dilution concerns, Viking Therapeutics shares suffered a sharp decline in Thursday's session. According to reports, the stock fell 15% following the pricing of its upsized $500 million combined offering. The company priced its common stock at $35.00 per share, alongside $225 million in 2.00% convertible senior notes due 2032, as it seeks to fund its clinical pipeline through aggressive capital raising.

The downward move in VKTX resonated across the biotech sector, impacting peer performance. Per market data, Jaguar Health shares plunged 25% during the same period, highlighting broader investor sensitivity to secondary offerings in the current environment. The confirmed $35.00 pricing for VKTX represents a significant discount to the trading range observed on September 22, 2026, when the stock fluctuated between a high of $41.73 and a low of $36.34.

Following the plunge on September 24, 2026, market participants are closely watching whether VKTX can establish a floor at the $35.00 offering price. With no major catalysts identified in the upcoming economic calendar for the next week, investor attention will remain on the stock's ability to absorb the additional equity and debt supply while monitoring for any further technical breakdown below the new pricing levels.